RBS2418, Tremelimumab, and Durvalumab for Advanced Unresectable Hepatocellular Carcinoma

This study focuses on testing a combination of medications for people with advanced liver cancer, specifically those whose cancer cannot be surgically removed. The aim is to see how well the new drug RBS2418 works when used with other drugs, Tremelimumab and Durvalumab, which are already given as a standard treatment. Participants need to have a certain level of physical health and a life expectancy of at least 12 weeks to join the study. This research is important because it could lead to better treatment options for those with advanced liver cancer, who currently have limited choices. Participants in the study will be divided into groups, with up to 220 people involved. Some will receive RBS2418 at different doses along with the standard treatment, while others will get the standard treatment alone. The treatment is given in cycles that last 28 days and can continue for up to two years, or until the cancer progresses, the participant leaves the study, or the study ends. Researchers will closely monitor any side effects, noting their severity according to standard guidelines. Side effects will be tracked for up to 30 days after the last dose of the study drug, and serious side effects will be monitored for up to 90 days after stopping the medication.